Sean  Maduck net worth and biography

Sean Maduck Biography and Net Worth

Mr. Maduck was named Corcept’s Chief Commercial Officer in 2020. Prior to that he was Corcept’s Senior Vice President, Commercial. Before that, he was the company’s Vice President, Sales & Marketing. Mr. Maduck joined Corcept in 2012, bringing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R. Hambrecht + Company. He currently serves on the Board of Directors of the Cancer Support Community – San Francisco Bay Area. Mr. Maduck earned an AB from Dartmouth College, a BE in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College and a Masters in Management from the Stanford Graduate School of Business.

What is Sean Maduck's net worth?

The estimated net worth of Sean Maduck is at least $1.90 million as of March 18th, 2024. Mr. Maduck owns 75,222 shares of Corcept Therapeutics stock worth more than $1,904,621 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Maduck may own. Additionally, Mr. Maduck receives an annual salary of $823,420.00 as Insider at Corcept Therapeutics. Learn More about Sean Maduck's net worth.

How old is Sean Maduck?

Mr. Maduck is currently 46 years old. There are 7 older executives and no younger executives at Corcept Therapeutics. The oldest executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who is 67 years old. Learn More on Sean Maduck's age.

What is Sean Maduck's salary?

As the Insider of Corcept Therapeutics Incorporated, Mr. Maduck earns $823,420.00 per year. There are 3 executives that earn more than Mr. Maduck. The highest earning executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who commands a salary of $1,820,000.00 per year. Learn More on Sean Maduck's salary.

How do I contact Sean Maduck?

The corporate mailing address for Mr. Maduck and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Sean Maduck's contact information.

Has Sean Maduck been buying or selling shares of Corcept Therapeutics?

During the last quarter, Sean Maduck has sold $1,133,430.96 in shares of Corcept Therapeutics stock. Most recently, Sean Maduck sold 17,219 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $25.00, for a transaction totalling $430,475.00. Following the completion of the sale, the insider now directly owns 75,222 shares of the company's stock, valued at $1,880,550. Learn More on Sean Maduck's trading history.

Who are Corcept Therapeutics' active insiders?

Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.

Are insiders buying or selling shares of Corcept Therapeutics?

In the last year, insiders at the biotechnology company sold shares 32 times. They sold a total of 266,012 shares worth more than $7,383,113.80. The most recent insider tranaction occured on March, 18th when insider Sean Maduck sold 17,219 shares worth more than $430,475.00. Insiders at Corcept Therapeutics own 19.8% of the company. Learn More about insider trades at Corcept Therapeutics.

Information on this page was last updated on 3/18/2024.

Sean Maduck Insider Trading History at Corcept Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/18/2024Sell17,219$25.00$430,475.0075,222View SEC Filing Icon  
2/16/2024Sell27,068$25.97$702,955.9674,455View SEC Filing Icon  
12/1/2023Sell25,000$25.56$639,000.0073,291View SEC Filing Icon  
11/1/2023Sell5,112$28.08$143,544.9673,291View SEC Filing Icon  
10/10/2023Sell18,471$27.29$504,073.5973,291View SEC Filing Icon  
10/6/2023Sell3,498$27.24$95,285.5273,610View SEC Filing Icon  
10/2/2023Sell3,031$27.24$82,564.4473,610View SEC Filing Icon  
9/19/2023Sell25,000$32.48$812,000.0073,610View SEC Filing Icon  
12/1/2022Sell625$25.28$15,800.0056,462View SEC Filing Icon  
11/10/2022Sell25,000$25.57$639,250.0056,462View SEC Filing Icon  
10/3/2022Sell25,000$25.64$641,000.0056,462View SEC Filing Icon  
8/9/2022Sell200$28.70$5,740.0040,024View SEC Filing Icon  
7/18/2022Sell25,000$27.37$684,250.0040,024View SEC Filing Icon  
10/5/2021Sell637$20.00$12,740.00View SEC Filing Icon  
10/1/2021Sell24,363$20.00$487,260.00View SEC Filing Icon  
9/1/2021Sell25,000$21.40$535,000.0065,024View SEC Filing Icon  
8/3/2021Sell25,000$21.18$529,500.0065,024View SEC Filing Icon  
7/7/2021Sell25,000$22.19$554,750.00View SEC Filing Icon  
2/16/2021Sell8,989$28.25$253,939.2533,424View SEC Filing Icon  
2/11/2021Sell3,400$29.78$101,252.0033,424View SEC Filing Icon  
12/12/2018Sell60,000$19.01$1,140,600.0065,015View SEC Filing Icon  
See Full Table

Sean Maduck Buying and Selling Activity at Corcept Therapeutics

This chart shows Sean Maduck's buying and selling at Corcept Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corcept Therapeutics Company Overview

Corcept Therapeutics logo
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $25.32
Low: $25.19
High: $25.58

50 Day Range

MA: $23.33
Low: $21.10
High: $25.32

2 Week Range

Now: $25.32
Low: $20.87
High: $34.28

Volume

57,654 shs

Average Volume

1,593,280 shs

Market Capitalization

$2.62 billion

P/E Ratio

26.65

Dividend Yield

N/A

Beta

0.47